Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sensitization of non-M3 AML blasts to ATRA by tranylcypromine (LSD1 inhibitor)
DRKS00006055Phase 2Recruiting
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tranylcypromine, tretinoin and cytarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (4 arms), sponsored by Universitätsklinikum Freiburg. Started Jul 2015; status: recruiting.
02
Drugs
tranylcyprominetretinoincytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on DRKS00006055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00006055.